HIV Snippets: A Podcast Series

This continuing pharmacy education activity is provided by Vindico Medical Education.

This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

RELEASE DATE

June 15, 2022

EXPIRATION DATE

June 14, 2023

Overview

Antiretroviral therapy (ART) for treating HIV has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already-diverse field of HIV treatment. In this CPE activity, participants will listen to expert faculty in a series of 4 podcasts. The faculty will explore various aspects of HIV management, including recent advances in pre-exposure prophylaxis (PrEP), use of 3-drug versus 2-drug regimens, individualizing ART regimens in aging patients with HIV, as well as the management of patients with HIV who struggle with stigma and/or adherence.

Target Audience

The intended audience for this activity is pharmacists involved in the management of patients with or at risk for HIV.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Explore how pre-exposure prophylaxis (PrEP) for HIV can successfully be implemented into clinical practice using an interprofessional approach.
  • Assess the latest evidence regarding the selection of antiretroviral regimens in aging patients with HIV.
  • Recognize the need for antiretroviral treatment regimens that improve patient adherence to therapy.
  • Compare the use of 3-drug versus 2-drug antiretroviral regimens in terms of efficacy, safety, and meeting the needs of individual patients with HIV.

Activity Chair

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Investigator, Lundquist Institute
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA
Relevant Disclosures:
Consultant: Gilead, GlaxoSmithKline/ViiV, Merck
Independent Research Contractor: Gilead, GlaxoSmithKline/ViiV, Merck

Faculty

Melissa E. Badowski, PharmD, MPH, FCCP, FIDSA, BCIDP, BCPS, AAHIVP
Clinical Associate Professor
Section of Infectious Diseases Pharmacotherapy
Department of Pharmacy Practice
University of Illinois at Chicago, College of Pharmacy
Chicago, IL
Relevant Disclosures:
No relevant financial relationships to disclose.

Meredith E. Clement, MD
Assistant Professor
Infectious Diseases
Louisiana State University Health Sciences Center
New Orleans, LA
Relevant Disclosures:
Advisor: Roche, ViiV
Independent Research Contractor (paid to institution): Gilead, Janssen, ViiV

Joseph J. Eron, Jr., MD
Professor of Medicine
Division of Infectious Diseases
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, NC
Relevant Disclosures:
Consultant: Gilead, Merck, ViiV
Independent Research Contractor: Gilead, Janssen, ViiV

Chloe Orkin, MBBCh, FRCP
Consultant Physician, Barts Health NHS Trust
Clinical Lead for COVID 19 Research at Barts Health NHS Trust
Lead for HIV and HIV/Hep C Research
Athena Swan Chair, Queen Mary, University of London School of Medicine
London, United Kingdom
Relevant Disclosures:
Advisor: Gilead, GlaxoSmithKline, Janssen, Merck, ViiV
Speaker Contracted by Ineligible Company: Gilead, GlaxoSmithKline, Janssen, Merck, ViiV
Independent Research Contractor: Gilead, GlaxoSmithKline, Janssen, Merck, ViiV

Reviewers

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
No relevant financial relationships to disclose.

Vindico Medical Education Staff

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

Vindico Medical Education adheres to the ACPE’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation

acpeVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Credit Designation

This program is acceptable for 1.25 contact hour of ACPE Continuing Education Credit. The ACPE Universal Program Number, 0482-0000-22-014-H02-P, is effective 06/15/2022. This is a knowledge-based activity and there is no fee to attend.

This enduring material is approved for 1 year from the date of original release, June 15, 2022, to June 14, 2023.

How to Participate in This Activity and Obtain CPE Credit

To participate in this activity, you must read the objectives, answer the polling and pretest questions, listen to the podcasts, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 out of 6 of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue Statement of Continuing Pharmacy Education Credit.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

ADA Compliance

In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Podcast is available upon request. Requests should include the Podcast title and can be emailed to CME@VindicoCME.com. Requests will be honored within 3-5 business days.

Educational Tools

For downloadable educational resources, visit below.

For a full list of all the educational tools available through Vindico Medical Education, please visit: www.VindicoCME.com/educationaltools

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA–approved or investigational use of products/devices.

Copyright

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CPE Questions?

Contact us at CME@VindicoCME.com